Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia

Ide-cell enhances health-related quality of life for refractory multiple myeloma

Zanidatamab, palbociclib and fulvestrant show positive results in treating HER2+/HR+ mBC

Toripalimab and metronomic chemotherapy show efficacy in treating in HER2-negative metastatic breast cancer

BrECADD combined with PET2-guided treatment sets a new benchmark for the treatment of newly diagnosed advanced-stage cHL

Ponatinib is superior to imatinib in combination with chemotherapy for newly diagnosed Ph+ ALL

Cancer care in Needle Hospital, Hargeisa, Somaliland

Relapsed refractory multiple myeloma

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer

ESMO 2023: Highlights and analysis

Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer